MACFARLAN SMITH LIMITED

SC035640
Active United Kingdom

Manufacture of basic pharmaceutical products

330 employees website.com
Life sciences and medical technology Manufacture of basic pharmaceutical products
M

MACFARLAN SMITH LIMITED

SC035640

Manufacture of basic pharmaceutical products

Founded 12 Sept 1960 Active United Kingdom 330 employees website.com
Life sciences and medical technology Manufacture of basic pharmaceutical products
Accounts Submitted 23 Jun 2026 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 27 Jan 2026 Next due 8 Feb 2027 7 months remaining
Net assets £68M £39M 2024 year on year
Total assets £94M £80M 2024 year on year
Total Liabilities £26M £41M 2024 year on year
Charges 4
4 satisfied

Contact & Details

Contact

Telephone

0800 000 0000

Website

www.example.com

Full company profile for MACFARLAN SMITH LIMITED (SC035640), an active life sciences and medical technology company based in United Kingdom. Incorporated 12 Sept 1960. Manufacture of basic pharmaceutical products. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Balance Sheet & P&L (2014–2024)

Cash in Bank

£8.93M

Increased by £1.25M (+16%)

Net Assets

£67.76M

Decreased by £39.31M (-37%)

Total Liabilities

£25.99M

Decreased by £40.56M (-61%)

Turnover

£77.85M

Decreased by £27.02M (-26%)

Employees

330

Decreased by 30 (-8%)

Debt Ratio

28%

Decreased by 10 (-26%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 8,833,845 Shares £8.83m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
19 Dec 20258,833,845£8.83m£1

Officers

Officers

1 active 2 resigned
Status
Craig Macian GrantDirectorBritishUnited Kingdom5613 Oct 2020Active

Shareholders

Shareholders (2)

Veranova 1 Ltd
55.3%
9,036,115
Veranova 2 Ltd
44.7%
7,297,730

Persons with Significant Control

Persons with Significant Control (2)

2 Active 2 Ceased

Veranova 1 Ltd.

United Kingdom

Active
Notified 31 May 2022
Nature of Control
  • Ownership Of Shares 50 To 75 Percent,voting Rights 50 To 75 Percent

Veranova 2 Ltd.

United Kingdom

Active
Notified 31 May 2022
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Meconic Limited

Ceased 7 May 2019

Ceased

Johnson Matthey Plc

Ceased 31 May 2022

Ceased

Group Structure

Group Structure

VERANOVA 1 LTD. united kingdom
VERANOVA 2 LTD. united kingdom
MACFARLAN SMITH LIMITED Current Company

Charges

Charges

4 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
23 Jun 2026AccountsAnnual accounts made up to 31 Dec 2025
22 May 2026OfficersTermination of David Martin Payne as director on 21 May 2026
27 Jan 2026Confirmation StatementConfirmation statement made on 25 Jan 2026 with updates
9 Jan 2026Persons With Significant ControlChange to Veranova 1 Ltd. as a person with significant control on 31 May 2022
19 Dec 2025CapitalAllotment of shares (GBP 16,333,845) on 19 Dec 2025
23 Jun 2026 Accounts

Annual accounts made up to 31 Dec 2025

22 May 2026 Officers

Termination of David Martin Payne as director on 21 May 2026

27 Jan 2026 Confirmation Statement

Confirmation statement made on 25 Jan 2026 with updates

9 Jan 2026 Persons With Significant Control

Change to Veranova 1 Ltd. as a person with significant control on 31 May 2022

19 Dec 2025 Capital

Allotment of shares (GBP 16,333,845) on 19 Dec 2025

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

2 weeks ago on 23 Jun 2026

Termination of David Martin Payne as director on 21 May 2026

1 months ago on 22 May 2026

Confirmation statement made on 25 Jan 2026 with updates

5 months ago on 27 Jan 2026

Change to Veranova 1 Ltd. as a person with significant control on 31 May 2022

6 months ago on 9 Jan 2026

Allotment of shares (GBP 16,333,845) on 19 Dec 2025

6 months ago on 19 Dec 2025